Switching from Beraprost to Selexipag in the Treatment of Pulmonary Arterial Hypertension: Insights from a Phase IV Study of the Japanese Registry (The EXCEL Study: EXChange from bEraprost to seLexipag Study).

Pharmaceuticals (Basel) · 2024 · PMC11124036 · PMID 38794126

Europe PMC DOI

hedged sentence

0.0690

closest p · 1.4× alpha

0.0690

boldest claim

The sentences

did not reach statistical significancep = 0.069so close (0.05 < p ≤ 0.1)

The cardiac index demonstrated an increase from 2.95 ± 0.13 (±SE) L/min/m 2 to 3.17 ± 0.16 L/min/m 2 , but this increase also did not reach statistical significance ( p = 0.069).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.